Oral Mucositis - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Oral Mucositis Emerging Therapy and TPP Insights

Thelansis's "Oral Mucositis Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Oral Mucositis Overview

Oral mucositis is a painful inflammatory injury of the oral mucosa that commonly develops during chemotherapy, radiotherapy, or hematopoietic stem cell transplantation, often disrupting nutrition, quality of life, and cancer treatment. Although palifermin can reduce severe mucositis in selected high-risk transplant patients, there is still no broadly effective therapy that reliably prevents or treats the condition across all cancer settings. As a result, supportive care-including oral hygiene protocols, cryotherapy, photobiomodulation, protective coatings, and pain management-remains the foundation of treatment. Growing evidence suggests that inflammatory pathways, tissue repair mechanisms, and the oral microbiome all influence disease severity, driving development of combination therapies that target multiple biological processes. For stakeholders, oral mucositis remains a significant supportive-care opportunity where substantial unmet clinical need persists despite decades of research.

Key Highlights

• In Germany, diagnosed incident Oral Mucositis cases are projected to increase from 562,562 in 2025 to 602,105 by 2035.
• Oral Mucositis is a common complication of chemotherapy and radiotherapy, significantly impacting patient quality of life and treatment adherence.
• Severe cases may lead to treatment interruptions, increased infection risk, and higher healthcare costs.
• Significant unmet need remains for therapies that effectively prevent and manage oral mucosal injury.

Market Overview

• The Germany Oral Mucositis market is projected to grow from $55M in 2025 to $130M by 2035.
• Market growth is driven by:
• Increasing cancer incidence and use of intensive anticancer therapies
• Growing adoption of supportive care and novel preventive treatments
• Future growth will depend on therapies capable of preventing severe mucositis and improving treatment continuity.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• EpicentRx, Inc.
• OncoZenge AB
• MitoImmune Therapeutics